Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Natural products or organic compounds isolated from natural sources as primary or secondary metabolites have inspired numerous drugs. It is not an overstatement that the majority of medicines in clinics, even in the 21st century, have been derived from natural resources despite the decline of industry research into natural products due to a variety of drawbacks. Saffron crocus, considered to be the most valuable spice by weight, and its bioactive constituents, have been studied for the treatment of a wide range of pathologies, including neuropsychiatric and neurodegenerative disorders, cancer, diabetes, and even cardiovascular diseases. In this book on the chemistry, pharmacology, and therapeutic potential of Crocus sativus L. extract and its constituents, we aimed to assess new advances in the understanding of the therapeutic action of saffron and its constituents in targeting different pathologies. In this context, eight original research articles covering recent advances in the therapeutic actions of saffron and its ingredients in different diseases are reported. Two studies reporting novel methods regarding the bioanalysis of saffron extracts have been included. The collection is completed with two very interesting reviews reporting advances in the fields of schizophrenia and cancer. In conclusion, in this book, we are delighted to have received several contributions that we hope will provide new and interesting information for the scientific community on the chemistry, pharmacology, and therapeutic potential of Crocus sativus L. extract and its constituents.

saffron --- affron® --- depression --- anxiety --- antioxidant --- crocins --- glucose --- β-pancreatic cells --- insulin --- pck1 --- neuroprotective activity --- P2X7 receptor --- fraction --- flumazenil --- rat --- Crocus sativus --- cancer --- anticancer activity --- chemoprevention --- clinical trials --- patents --- anesthetic ketamine --- memory --- Crocus sativus L. --- schizophrenia --- crocetin --- pubertal testis --- X-rays --- radiotherapy --- fertility preservation --- SIRT1 --- HuR --- oxidative stress --- autophagy --- crocin --- picrocrocin --- safranal --- dietary supplement --- nutraceutical --- Crocus sativus L. (Iridaceae) --- reversed-phase UPLC --- metabolomics --- HR MS --- inflammatory bowel disease --- gut microbiota --- colitis --- cytokines --- colorectal cancer --- HCT116 --- MLH1 --- MSH3 --- DNA damage and repair --- apoptosis --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Natural products or organic compounds isolated from natural sources as primary or secondary metabolites have inspired numerous drugs. It is not an overstatement that the majority of medicines in clinics, even in the 21st century, have been derived from natural resources despite the decline of industry research into natural products due to a variety of drawbacks. Saffron crocus, considered to be the most valuable spice by weight, and its bioactive constituents, have been studied for the treatment of a wide range of pathologies, including neuropsychiatric and neurodegenerative disorders, cancer, diabetes, and even cardiovascular diseases. In this book on the chemistry, pharmacology, and therapeutic potential of Crocus sativus L. extract and its constituents, we aimed to assess new advances in the understanding of the therapeutic action of saffron and its constituents in targeting different pathologies. In this context, eight original research articles covering recent advances in the therapeutic actions of saffron and its ingredients in different diseases are reported. Two studies reporting novel methods regarding the bioanalysis of saffron extracts have been included. The collection is completed with two very interesting reviews reporting advances in the fields of schizophrenia and cancer. In conclusion, in this book, we are delighted to have received several contributions that we hope will provide new and interesting information for the scientific community on the chemistry, pharmacology, and therapeutic potential of Crocus sativus L. extract and its constituents.

Medicine --- saffron --- affron® --- depression --- anxiety --- antioxidant --- crocins --- glucose --- β-pancreatic cells --- insulin --- pck1 --- neuroprotective activity --- P2X7 receptor --- fraction --- flumazenil --- rat --- Crocus sativus --- cancer --- anticancer activity --- chemoprevention --- clinical trials --- patents --- anesthetic ketamine --- memory --- Crocus sativus L. --- schizophrenia --- crocetin --- pubertal testis --- X-rays --- radiotherapy --- fertility preservation --- SIRT1 --- HuR --- oxidative stress --- autophagy --- crocin --- picrocrocin --- safranal --- dietary supplement --- nutraceutical --- Crocus sativus L. (Iridaceae) --- reversed-phase UPLC --- metabolomics --- HR MS --- inflammatory bowel disease --- gut microbiota --- colitis --- cytokines --- colorectal cancer --- HCT116 --- MLH1 --- MSH3 --- DNA damage and repair --- apoptosis --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Alveolar epithelial cells (AECs) of the lung are important contributors to pulmonary immune functions and to pulmonary development and alveolar repair mechanisms following lung injury. AECI, together with the capillary endothelium, form the extremely thin barrier between alveolar air and blood. AECII produce and metabolize the surface-tension lowering and immune-modulating surfactant and are the progentiors of AECI. A great variety of processes rely on their normal functioning, including maintenance of the alveolar barrier; innate immune defense; and processes of differentiation, senescence, apoptosis, and autophagy. The wide range of AEC functions is nicely reflected by the diversity of topics addressed by the four review and eight original articles contained in this Special Issue of the International Journal of Molecular Sciences. Beyond the broad spectrum of topics, the authors of this issue also made use of an impressive variety of analytical methods, thus further illustrating the fascinating diversity of aspects related to AEC biology.

JAM-A --- P2X7 receptor --- mouse lung --- alveolar epithelium --- bleomycin-induced lung injury --- GSK-3β --- dietary sugar --- hyperglycemia --- lung mechanics --- alveolar septal composition --- physical activity --- extracellular matrix remodeling --- high-altitude pulmonary edema --- acute mountain sickness --- oxygen diffusion limitation --- surfactant protein B --- atelectrauma --- alveolar fluid --- acinar micromechanics --- acute lung injury --- autophagy --- lysosome --- lysosomal membrane permeability --- mitochondria --- pneumocyte --- microRNA-21 --- alveolar micromechanics --- structural remodeling --- inflammatory signaling --- lung --- alveolus --- type 1 alveolar epithelial cell --- type 2 alveolar epithelial cell --- focused ion beam scanning electron microscopy --- 3D reconstruction --- carbon dioxide --- hypercapnia --- Na,K-ATPase --- endoplasmic reticulum --- sodium transport --- protein oxidation --- alveolar epithelial cells --- pulmonary fibrosis --- epithelial cell dysfunction --- stem cell exhaustion --- pneumonia --- necrotizing --- regeneration --- model --- bovine --- chlamydia --- alveoli --- air-blood barrier --- epithelium --- air-liquid interface --- alveolar lining layer --- glycocalyx --- surfactant --- lung injury --- lung regeneration

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.

apoptosis --- fucoidan --- hepatocellular carcinoma --- reactive oxygen species --- 3-alkylpyridinium polymers --- nicotine --- nicotinic acetylcholine receptor --- non-small cell lung carcinoma --- melanoma --- sinulariolide --- proteomic --- mitochondria --- caspase cascade --- marine fungus --- sediment --- anthranilic acid --- Penicillium paneum --- cytotoxicity --- dibromotyrosine --- mitochondrial dysfunction --- oxidative stress --- topoisomerase --- epigonal organ --- bonnethead shark --- Jurkat --- tumor cell line --- hippuristanol --- PEL --- AP-1 --- STAT3 --- Akt --- colorectal cancer --- marine mollusc --- brominated indoles --- shrimp --- chemoprevention --- fatty acids --- carotenoids --- cancer --- nanoparticle --- osteosarcoma --- lung metastasis --- elisidepsin --- lipid rafts --- hydroxylated lipids --- fatty acid 2-hydroxylase --- cooperative binding --- membrane permeabilization --- marine organisms --- polysaccharides --- anticancer --- anticarcinogenic --- mechanisms of action --- fumigaclavine C --- anti-proliferation --- mitochondrial pathway --- anti-cancer --- anti-proliferative --- carotenoid --- cell cycle arrest --- fucoxanthin --- azoxymethane --- bioactive natural product --- isatin --- in vivo model --- Marthasterias glacialis L. --- palmitic acid --- ER-stress --- CHOP --- Antibody Drug Conjugates (ADCs) --- marine antitumor agents --- clinical trials --- approved antitumor agents --- AD0157 --- angiogenesis --- marine drug --- pyrrolidinedione --- secondary metabolites --- cancer preventive --- chemopreventive --- trabectedin --- plitidepsin --- tumor-associated macrophages --- tumor microenvironment --- preclinical --- anticancer immunity --- antiangiogenesis --- fascaplysin --- cyclin-dependent kinase --- small cell lung cancer --- camptothecin --- poly(ADP-ribose)-polymerase inhibitor --- breast cancer --- seaweed --- therapeutic compounds --- autophagy --- marine drugs --- autophagy inhibitors --- autophagy inducers --- macrolide --- programmed cell death --- energy stress --- araguspongine C --- c-Met --- HER2 --- gemcitabine --- pazopanib --- phase I --- safety --- soft tissue sarcoma --- pachastrissamine --- jaspine B --- carbocyclic analogue --- sphingosine kinase inhibitor --- molecular modeling --- ET-743 --- DNA minor groove binder --- chemotherapy --- bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM) --- anti-metastatic activity --- cell adhesion --- β1-integrin --- FAK --- BEL-7402 cell --- triterpene glycosides --- sea cucumbers --- antitumor activities --- arrest of cell cycle --- antibacterial --- marangucyclines --- deep-sea --- Streptomyces sp. SCSIO 11594 --- LS-1 --- SNU-C5/5-FU --- TGF-β signaling --- carcinoembryonic antigen --- kalkitoxin --- Moorea producens --- mitochondria toxin --- VEGF --- angiogenesis inhibitor --- hypoxia-inducible factor-1 --- HIF-1 --- Lyngbya majuscula --- marine metabolites --- SZ-685C --- nonfunctioning pituitary adenomas --- Ecklonia cava --- phlorotannins --- dieckol --- migration --- sipholenol A --- ABC transporter --- multidrug resistance --- P-gp/ABCB1 --- BCRP/ABCG2 --- MRP1/ABCC1 --- marine natural products --- glioblastoma --- xyloketal B --- proliferation --- TRPM7 --- marine compound --- ribosomal protein genes --- snoRNA --- FAU --- RPS30 --- SNORA62 --- evolution --- Porifera --- n/a --- Penicillium brevicompactum --- Brevianamide --- Mycochromenic acid derivative --- antifouling --- Caribbean sponge --- plakortide --- endoperoxide --- leukemia --- multi-drug resistant leukemia --- Sarcophyton ehrenbergi --- soft coral --- terpenes --- cembranoids --- cytotoxic activity --- molecular docking --- uveal melanoma --- virtual screening --- Topo I inhibitor --- low toxic --- natural product --- Ulva fasciata --- selenium-containing polysaccharide-protein complex --- pseudopterosin --- NF-κB --- p65 --- inflammation --- cytokine release --- IL-6 --- TNFα --- MCP-1 --- glucocorticoid receptor --- paulomycins --- Micromonospora --- antitumor --- Cantabrian Sea-derived actinobacteria --- puupehenones --- sponges --- antiangiogenic --- antitumoral --- porifera/sponge --- cancer genes --- molecular oncology --- bromophenol --- molecular mechanisms --- cell cycle --- PI3K/Akt --- p38/ERK --- ROS --- human lung cancer --- glycosaminoglycans --- antiproliferative --- heparan sulphate --- gliotoxin --- NSCLC --- adriamycin resistance --- Sepia ink polysaccharides --- antitumour --- chemosensitization --- anticoagulation --- sea anemone --- drug discovery --- endothelial cells --- RGD motif --- kunitz type inhibitor --- prostate cancer --- antioxidant --- natural marine compounds --- marine biotechnology --- microalgae --- marine sponges --- Aeroplysinin --- Isofistularin --- pheochromocytoma and paraganglioma --- metastasis --- cancer progression --- cell adhesion molecules --- integrin β1 --- hypoxia --- phycocyanin --- non-small cell lung cancer --- NF-κB signaling --- marine-derived drugs --- bioanalysis --- chromatography --- manzamine A --- epithelial–mesenchymal transition --- lung cancer --- circulating tumor cells --- signal transduction --- cisplatin --- Lampetra morii --- buccal gland --- cystatin F --- anti-angiogenesis --- cystatin superfamily --- Antimicrobial peptide (AMP) --- Tilapia piscidin 4 (TP4) --- non-small cell lung cancer (NSCLC) --- itampolin A --- FBDD --- p38α --- novel inhibitor --- tetracenomycin X --- cyclin D1 --- proteasomal degradation --- p38 --- c-JUN --- λ-carrageenan --- heparanase --- anticoagulant --- depolymerisation --- cell migration --- Aspergillus --- naphthopyrones --- endophytic fungus --- Leathesia nana --- mangrove-derived actinomycete --- ansamycins --- divergolides --- apoptosis-inducing activity --- actinomycin --- EMT --- invasion --- low molecular weight fucoidan extract --- N-Ras --- neuroblastoma-rat sarcoma --- Cancer --- programmed cell death-ligand 1 --- programmed cell death-ligand 2 --- human sarcoma cell line (HT1080 cells) --- human normal diploid fibroblast (TIG-1 cells) --- chimera --- chemical conjugation --- anticancer agent --- hybridization --- α9-nicotinic acetylcholine receptors (nAChRs) --- breast cancer cells --- αO-conotoxin GeXIVA --- targeted therapy --- gorgonian --- Leptogorgia --- humulane sesquiterpenoids --- anticancer activity --- 12-deacetyl-12-epi-scalaradial --- HeLa cells --- Nur77 --- MAPK/ERK pathway --- Mycalin A --- C15 acetogenins --- synthetic analogues --- antiproliferative activity --- A375 and HeLa cell lines --- polyoxygenated steroids --- sponge --- Haliclona gracilis --- Thalassia testudinum --- thalassiolin B --- polyphenols --- CYP1A1 --- benzo[a]pyrene --- JNK1/2 --- natural products --- synergism --- A549 cells --- cytoskeleton --- P2X7 receptor --- pollution --- anti-angiogenic --- gene expression --- HSP90 --- inhibitor --- epithelial-mesenchymal transition